Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome

This study has been completed.
Sponsor:
Information provided by:
Royan Institute
ClinicalTrials.gov Identifier:
NCT00947713
First received: July 25, 2009
Last updated: July 14, 2011
Last verified: April 2010
  Purpose

The purpose of this study is to compare the effectiveness of low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate to induce ovulation and its endocrine response in patients who had previously failed to ovulate on clomiphen citrate alone. The investigators will also compare the effectiveness and endocrine response of this approach with the regimen of adding HMG to clomiphen citrate.


Condition Intervention Phase
Endocrine System Diseases
Gonadal Disorders
Drug: low dose human chorionic gonadotropin
Drug: Clomiphen citrate plus HMG
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With HMG in PCOs Patients With Previous Clomiphene Citrate (CC)-Resistant Anovulation

Resource links provided by NLM:


Further study details as provided by Royan Institute:

Primary Outcome Measures:
  • Multiple pregnancy rates, OHSS rate [ Time Frame: Within 20 months after recruiting ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pregnancy rate [ Time Frame: Within 20 months after recruiting ] [ Designated as safety issue: No ]
  • The total dose of ovarian stimulation drugs [ Time Frame: Within 20 months after recruiting ] [ Designated as safety issue: No ]
  • The number of embryos available for transfer [ Time Frame: Within 20 months after recruiting ] [ Designated as safety issue: No ]
  • The embryo implantation rate and The live birth rate [ Time Frame: Within 20 months after recruiting ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: August 2009
Study Completion Date: December 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose hCG group Drug: low dose human chorionic gonadotropin
patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
Other Name: human chorionic gonadotropin
Active Comparator: Clomiphen citrate plus HMG Drug: Clomiphen citrate plus HMG
patients will receive Clomiphen Citrate plus HMG

Detailed Description:

Infertile women with PCOS, who have showed resistance to Clomiphen Citrate (150 mg- 5 days) in a previous IUI treatment cycle at Royan Institute (Infertility and Reproductive Medicine Research Centre) will enroll in this prospective randomized clinical trial study and will randomly be divided into three groups.

The study protocol will be assessed by an independent institutional review board and Royan ethics committee. All subjects will be given the written informed consent.

Control group (CC/hMG) will receive the 100 mg CC on days 3 to 7 of that cycle but will receive 150 mg human menopausal gonadotropin (HMG) during days of 7, 8, and 9. One of experimental Group (group B) will receive a 100 mg dose of CC but will receive a 200 IU Human chorionic gonadotropin (hCG; Choriomon; IBSA, Switzerland) intramuscular injection daily when the largest follicle is 12 mm or larger mean diameter. Other experimental group (Group C) will receive a 100 mg dose of CC but will receive a 200 IU Human chorionic gonadotropin (hCG; Choriomon; IBSA, Switzerland) intramuscular injection daily From day 9(without attention to follicle size). In both experimental groups HCG administration will be continued until the largest follicle is 18-20 mm.

Ultrasound measurements of follicle number and growth, ovulation, gestational sac, and serum hormonal levels will be recorded and compared between two groups.

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women with PCOS diagnosed by the Rotterdam criteria
  • Previously documented dominant follicle or follicles (R12 mm mean diameter) on transvaginal Ultrasound follicular monitoring while receiving CC at the 150-mg dose in our clinic but have failed to ovulate;
  • Primary infertility
  • Documented normal uterine cavity and patent tubes by either hysterosalpingogram or laparoscopy and hysteroscopy;
  • Male partner had to have a normal semen analysis by World Health Organization criteria.

Exclusion Criteria:

  • previous history of IVF or ICSI treatments.
  • History of hormonal treatment within recent three month (Except OCP, progesterone).
  • History of ovarian cutter or Ovarian drilling.
  • BMI higher than 30.
  • The presence of ovarian cyst (more than 30 mm) during third cycle ultrasound.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00947713

Locations
Iran, Islamic Republic of
Royan institute, Reproductive Medicine Research Centre, ACECR
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
Royan Institute
Investigators
Principal Investigator: Mahnaz Ashrafi Royan institute, Reproductive Medicine Research Centre, ACECR
  More Information

Additional Information:
No publications provided

Responsible Party: Hamid Gourabi, Chief, Royan institute
ClinicalTrials.gov Identifier: NCT00947713     History of Changes
Other Study ID Numbers: Royan-Emb-002
Study First Received: July 25, 2009
Last Updated: July 14, 2011
Health Authority: Iran: Ministry of Health

Keywords provided by Royan Institute:
Human chorionic gonadotropin
Clomiphene citrate
chronic anovulation
Polycystic Ovary Syndrome
Follicolugenesis

Additional relevant MeSH terms:
Anovulation
Endocrine System Diseases
Gonadal Disorders
Polycystic Ovary Syndrome
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Ovarian Cysts
Cysts
Neoplasms
Chorionic Gonadotropin
Clomiphene
Menotropins
Citric Acid
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Anticoagulants
Hematologic Agents
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Fertility Agents, Female
Fertility Agents
Selective Estrogen Receptor Modulators

ClinicalTrials.gov processed this record on July 24, 2014